Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: September 19, 2013
Event Date: September 19, 2013 (Notice of redemption)
Key Financial Metrics
This filing reports a specific debt redemption event rather than periodic financial performance metrics (revenue, profit, cash flow, or margins). The filing text does not provide a clear value for these operational metrics.
| Metric | Value |
|---|---|
| Debt Instrument | 8.00% Senior Subordinated Notes due 2016 |
| Principal Amount Redeemed | $300,000,000 |
| Redemption Price | 104.00% of aggregate principal amount |
| Estimated One-Time Expense | Approximately $17 million |
| Redemption Date | September 30, 2013 |
Material Changes
The Company provided irrevocable notice to redeem all remaining outstanding Notes. This action will reduce the Company's outstanding debt load by $300 million upon the redemption date.
Outlook, Risks, and Unusual Items
- Unusual Item: The redemption will incur a one-time expense of approximately $17 million, representing the premium paid over the principal amount.
- Management Commentary: The filing confirms the execution of the redemption notice but does not provide broader strategic commentary or future guidance.
- Risks/Contingencies: No specific risks or contingencies are detailed in this filing beyond the execution of the debt transaction.
Investor Verification Checklist
- Confirm the exact principal amount of Notes outstanding as of September 30, 2013, to verify the $300 million figure.
- Review the Company's cash position to ensure sufficient liquidity exists to fund the $312 million total redemption cost ($300M principal + $12M premium) plus accrued interest.
- Monitor the upcoming quarterly earnings report to see how the $17 million one-time expense is classified and its impact on net income.
- Verify the impact of this debt reduction on the Company's leverage ratios and interest expense coverage.